Ascendis Pharma A/S (ASND)

NMS – Real vaqt narxi. Valyuta: USD

255.46

+0.89 (0.35%)

Yopilishda: Aug 12, 2026, 4:00 PM EDT

256.35

+0.89 (0.35%)

Bozordan keyin: Aug 12, 2026, 5:19 PM EDT

06.08.2026

Ascendis to Report Second Quarter 2026 Financial Results and Provide Business Update on August 13, 2026

COPENHAGEN, Denmark, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it plans to report second quarter 2026 financial results and provide a business update on Thursday, August 13, 2026, before the open of the U.S. financial markets. Ascendis Pharma also plans to host a conference call and live webcast on August 13, 2026, at 8:00 a.m.

06.08.2026

Ascendis Announces COACH Week 78 Results and Provides Update on Achondroplasia Programs and YUVIWEL® Uptake in the U.S.

COPENHAGEN, Denmark, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today provided updates across its achondroplasia programs.

Videolar

No Data

There is no data to display

Press-relizlar

06.08.2026

Ascendis Announces COACH Week 78 Results and Provides Update on Achondroplasia Programs and YUVIWEL® Uptake in the U.S.

COPENHAGEN, Denmark, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today provided updates across its achondroplasia programs.

Ascendis Pharma A/S (ASND)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Ascendis Pharma A/S (ASND)

Ascendis to Report Second Quarter 2026 Financial Results and Provide Business Update on August 13, 2026

Ascendis Announces COACH Week 78 Results and Provides Update on Achondroplasia Programs and YUVIWEL® Uptake in the U.S.

Videolar

No Data

Press-relizlar

Ascendis Announces COACH Week 78 Results and Provides Update on Achondroplasia Programs and YUVIWEL® Uptake in the U.S.

Ascendis to Report Second Quarter 2026 Financial Results and Provide Business Update on August 13, 2026

Ascendis Announces COACH Week 78 Results and Provides Update on Achondroplasia Programs and YUVIWEL® Uptake in the U.S.

Videolar

No Data

Press-relizlar

Ascendis Announces COACH Week 78 Results and Provides Update on Achondroplasia Programs and YUVIWEL® Uptake in the U.S.

Search stocks

Ascendis Pharma A/S (ASND)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Ascendis Pharma A/S (ASND)

Ascendis to Report Second Quarter 2026 Financial Results and Provide Business Update on August 13, 2026

Ascendis Announces COACH Week 78 Results and Provides Update on Achondroplasia Programs and YUVIWEL® Uptake in the U.S.

Videolar

No Data

Press-relizlar

Ascendis Announces COACH Week 78 Results and Provides Update on Achondroplasia Programs and YUVIWEL® Uptake in the U.S.

Ascendis to Report Second Quarter 2026 Financial Results and Provide Business Update on August 13, 2026

Ascendis Announces COACH Week 78 Results and Provides Update on Achondroplasia Programs and YUVIWEL® Uptake in the U.S.

Videolar

No Data

Press-relizlar

Ascendis Announces COACH Week 78 Results and Provides Update on Achondroplasia Programs and YUVIWEL® Uptake in the U.S.